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diated drug sharing with 2-piece syringes. Scaling up substi-
tution therapy, especially heroin replacement, combined 
with reducing the supply of liquid drugs may decrease the 
prevalence of high-risk injecting behaviours related to the 
injecting of liquid drugs and drug injecting-related infec-
tions among IDUs in Lithuania.    Copyright © 2010 S. Karger AG, Basel 
 Introduction 
  Hungary (with a population of 10 million) and Lithu-
ania (with a population of 3 million) joined the European 
Union in 2004 after shaking off decades of Soviet rule in 
the early 1990s   [1, 2]  . Despite these similarities, the prev-
alence of HIV and HCV is very different in these 2 coun-
tries. Historically, only a few cases of HIV were diagnosed 
among injecting drug users (IDUs) in these countries be-
tween 1992 and 1996   [3]  . However, between 1997 and 
2007, while the HIV incidence in Hungary stayed low 
(between 0 and 3 cases per year), it increased in Lithuania 
(between 23 and 379 cases per year)  [3] . Studies in the past 
years among IDUs in Hungary detected no HIV preva-
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 Abstract 
 Despite   very similar political, drug policy and HIV prevention 
backgrounds, HIV and HCV prevalence is considerably differ-
ent in Hungary (low HIV and moderate HCV prevalence) and 
Lithuania (high HCV and moderate HIV prevalence). We   com-
pared the drug use profile of Hungarian (n = 215) and Lithu-
anian (n = 300) injecting drug users (IDUs). Overall, compared 
with IDUs in Hungary, IDUs in Lithuania often injected opi-
ates purchased in liquid form (‘shirka’), used and shared 
2-piece syringes (vs. 1-piece syringes) disproportionately 
more often, were less likely to acquire their syringes from le-
gal sources and had significantly more experience with in-
jected and less experience with non-injected drugs. It may 
not be liquid drugs per se that contribute to a higher preva-
lence of HCV and/or HIV, but it is probably factors associated 
with the injecting of liquid drugs, such as the wide-spread 
use and sharing of potentially contaminated 2-piece syring-
es acquired often from non-legal sources, and syringe-me-
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lence   [4, 5]  , while the prevalence of HIV among IDUs in 
Lithuania is as high as 10% in certain populations   [5] . 
Concerning HCV, between 1995 and 2007, at most 14 new 
IDU cases in 1 year were detected in Hungary, compared 
with as many as 55 in 1 year in Lithuania   [6]  , and HCV 
prevalence among IDUs is about 40% in Hungary and as 
high as 90% in Lithuania   [7] .
    While no historical data are available on trends of in-
jecting in the 2 countries, currently, problem drug use is 
more prevalent in Hungary (about 35 per 10,000 popula-
tion aged 15–65) than in Lithuania (17 per 10,000 popula-
tion aged 15–64) and IDU is less common in Hungary 
(about 6 per 10,000 population aged 15–64) than in Lithu-
ania (about 13 per 10,000 population aged 15–64)   [8, 9] . 
Data on trends of harm reduction reveal that HIV preven-
tion programmes started around the same time in both 
countries. Syringe exchange programmes are legal (since 
1994 in Hungary and since 1997 in Lithuania), and sy-
ringes can be purchased legally in pharmacies   [10]  . In ad-
dition, drug treatment is widely available in both Hun-
gary (since 1995) and Lithuania (since 1996)   [11] .  Drug 
injecting patterns may be different in the 2 countries: 
while Hungarian IDUs inject drugs that are purchased 
almost exclusively in powder form and use predominant-
ly 1-piece syringes, Lithuanian IDUs often inject drugs 
purchased in liquid form and often with 2-piece syringes 
(1-piece or low dead space syringes that have no removable 
needle and hold very little fluid when the plunger is fully 
depressed vs. 2-piece or high dead space syringes that have 
removable syringes and hold relatively large amounts of 
fluid when the plunger is fully depressed)   [4, 12–14] .
  Understanding the differences in the characteristics of 
populations with a similar HIV prevention background 
but different infection prevalence patterns may help de-
velop appropriate interventions to decrease the preva-
lence of drug-related infections among high-prevalence 
populations and keep the prevalence low in low-preva-
lence populations. The aim of this analysis was to com-
pare the individual background among Hungarian and 
Lithuanian IDUs and patterns of population mixing sus-
ceptibility, drug use, syringe use and sharing, structural 
background markers, and attitude and knowledge, and 
further, to provide suggestions for interventions.
  Methods 
  Setting and Participants 
  IDUs in both countries were recruited with traditional meth-
ods to reach hidden populations: in Budapest, Hungary, between 
October 2005 and December 2006 using street outreach, and in 
Vilnius, Lithuania, between March 2008 and May 2009 from the 
needle exchange programme of the Lithuanian AIDS Centre. In 
addition, participants in both cities were asked to bring in other 
IDUs who may be eligible to participate in the study. In Hungary, 
29% of participants were street recruited and 71% of participants 
were brought in by other participants, and in Lithuania, 6% of 
participants were recruited from the needle exchange programme 
and 94% were brought in by other participants. Those who self-
reported injecting drugs in the past 30 days or were  6 18 years old 
were eligible to participate. Data on recruitment success were not 
collected or were not possible for those who were invited to par-
ticipate by participants already enrolled in the study, thus differ-
ences between participants and non-participants cannot be as-
sessed. Self-report of injecting drugs was confirmed in both cities 
by inspecting injecting marks. Participants received a cash pay-
ment of HUF 2,000 (about EUR 8) in Budapest and food coupons 
worth LTL 20 (about EUR 8) in Vilnius for participation, and 
HUF 500 (about EUR 2) in Budapest and coupons worth LTL 10 
(about EUR 4) in Vilnius for bringing in other eligible partici-
pants. After signing an informed consent, eligible participants 
were administered an about 2-hour-long structured face-to-face 
survey, after which they received counselling about drug-related 
infectious diseases and their prevention and provided blood sam-
ples to be tested for infectious diseases. In Hungary, the Abbott 
ELISA test confirmed by Western blot was used for HIV antibody 
screening, and the HCV EIA 3.0 procedure for encoded antigens 
(recombinant c100-3, HC-31 and HC-34) confirmed by recombi-
nant immunoblot assay was used for HCV antibody screening. In 
Lithuania, the Abbott ELISA test Genscreen HIV1/2 (Biorad) 
confirmed by Western blot was used for HIV antibody screening, 
and the HCV EIA 3.0 (orthoclinical diagnostics) procedure for 
encoded antigens (recombinant c100-3, HC-31 and HC-34) con-
firmed by recombinant immunoblot assay was used for HCV an-
tibody screening.
    The wording of the questions that were used for this analysis 
was identical in both cities, except where specified. The question-
naires were originally in English, translated into Hungarian and 
Lithuanian, back translated, and altered, if necessary. The insti-
tutional review boards at the National Development and Research 
Institutes, Inc., in New York, N.Y., USA, and the Hungarian Acad-
emy of Sciences in Budapest, Hungary, approved all human sub-
jects procedures for the study in Budapest. The institutional re-
view boards at the Johns Hopkins Bloomberg School of Public 
Health, Baltimore, Md., USA, and the Lithuanian AIDS Centre 
approved all human subjects procedures for the study in Vilnius.
  Measures  and  Variables 
  Individual background variables were age and gender (male 
vs. female). Population mixing susceptibility variables were eth-
nicity (Roma, and, in Lithuania only, Russian and Polish), the 
number of languages participants spoke (1, 2, 3, 4 or more), any 
travel outside the capital and abroad in the past 12 months. Drug 
use pattern characteristics were calculated based on the questions 
‘how old were you when you first tried (drug name)’, ‘have you 
ever injected (drug name)’, ‘how often did you use (drug name) in 
the past 30 days injected’, ‘how often did you use (drug name) in 
the past 30 days non-injected’. The questions were asked for alto-
gether 24 drugs [‘korong’ (a mixture of hallucinogens) was in-
cluded only in Hungary, and opiates purchased in liquid form 
(‘shirka’) and amphetamines purchased in liquid form were in- Gyarmathy   /Neaigus   /Li   /Ujhelyi   /
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cluded only in Lithuania], and the open-ended ‘other drug’ (  ! 5% 
in each sample reported drugs other than those listed). Based on 
answers to these questions, we calculated the age at first use of 
legal drugs (alcohol or tobacco), age at first use of any illegal 
drugs, age at first drug injecting, the number of years as a non-
IDU, the number of drugs ever tried and ever injected, and the 
number of drugs (any and daily) injected and used non-injected 
in the past 30 days. Participants were also asked about which drug 
they injected most often in the past 30 days. Injecting equipment 
use and sharing variables were: using any 2-piece syringes (vs. us-
ing only 1-piece syringes), a composite variable assessing syringe 
sharing (reporting any receptive or distributive syringe sharing), 
and a composite variable assessing the sharing of injecting equip-
ment other than syringes [ any cookers or filters, or squirting 
drugs from one syringe into another syringe (syringe-mediated 
drug sharing)] in the past 30 days.
    Structural background markers assessed ever and currently 
being in treatment. In addition, participants were asked what 
percent of syringes they obtained from the syringe exchange 
themselves or through somebody else (primary or secondary ex-
change)   [15]  , from the pharmacy, or from their dealers. In Lithu-
ania only, participants reported what drugs they most often in-
jected with 1-piece and 2-piece syringes (where participants were 
able to select 1 of the above listed drugs). A combined HCV/HIV 
disclosure attitude variable was created based on agreement with 
both of the following statements: ‘those who are HCV infected 
should tell their injecting partners’ and ‘those who are HIV in-
fected should tell their injecting partners’. A composite HCV/
HIV knowledge score was calculated based on the number of cor-
rect answers to the 8 questions whether HCV and, respectively, 
HIV is transmitted sexually, with used syringes, with other used 
injecting equipment, and whether there is a vaccine. Sexual risk   
  variables assessed, in the past 30 days, the number of sex part-
ners, the number of sexual acts and whether condoms were used 
every time.
  Statistical  Analysis 
    2   analysis assessed differences in categorical variables, and 
the t test assessed differences in continuous variables between 
participants in Hungary versus Lithuania. Variables with at least 
marginal (p   !   0.20) association in the univariate analysis were 
chosen for logistic regression analysis. Multivariate logistic re-
gression with forward selection was used to identify the set of 
variables that showed a significant (p   !   0.05) association with re-
cruitment location. A structured forward selection procedure was 
used, whereby groups of highly correlated variables were exam-
ined and variables that were selected within the groups were then 
combined into a group for the final variable selection. Maximum 
likelihood estimates with corresponding p values are reported. 
Data management and analysis were preformed in SAS version 
9.2. Bar chars were created in Excel.
  R e s u l t s  
 Altogether, 215 participants were interviewed in Hun-
gary and 300 in Lithuania. Of the 186 who were tested in 
Hungary, 37% were HCV infected and nobody tested 
positive for HIV, and of the 297 who were tested in Lithu-
ania, 88% tested positive for HCV and 10% for HIV – sig-
nificant differences between the 2 study sites (  table 1  ). 
Just under a quarter in both sites were females (non-sig-
nificant difference), and Hungarian IDUs were signifi-
cantly younger. About a third (30%) of IDUs in Lithuania 
most often injected drugs purchased in liquid form, while 
none of the IDUs in Hungary mentioned liquid drugs in 
the ‘other drug’ category.
    In the univariate analysis, with the exception of age at 
first use of illegal drugs and ever being in treatment, all 
the population mixing susceptibility characteristics  ,  
drug use patterns, injecting equipment use and sharing 
characteristics, structural background markers, as well 
as attitude and knowledge variables were significantly 
different ( table 1 ,  2 ). IDUs in Hungary used a higher num-
ber of non-injected drugs ( fig. 1 ), while IDUs in Lithuania 
injected not only somewhat different, but also a higher 
number of drugs (  fig. 2  ). While IDUs in Lithuania had a 
significantly higher number of sexual partners, there 
were no further significant differences in sexual risk 
characteristics.
    Multivariate analysis (   table 3   ) showed that IDUs in 
Lithuania were significantly more likely than IDUs in 
Hungary to engage in (either receptive or distributive) sy-
ringe sharing, use any 2-piece syringes, speak 3 or more 
languages, inject daily, know more about HIV and HCV, 
have injected a higher number of drugs both on a daily 
basis in the past 30 days and ever, and are older the first 
time of using any legal drugs (alcohol or tobacco). In ad-
dition, IDUs in Hungary were significantly more likely 
than IDUs in Lithuania to inject amphetamines, get all 
their syringes from legal sources (either the pharmacy or 
the needle exchange), and have used a higher number of 
non-injected drugs both on a daily basis in the past 30 
days and ever.
    We performed a post-hoc analysis of this sample and 
compared IDUs in Lithuania who ever in their lives in-
jected opiates purchased in liquid form (n = 286) with 
those who never did (n = 14). Those IDUs who reported 
ever injecting liquid opiates had a significantly higher 
prevalence of both HCV (90 vs. 36%) and HIV (10 vs. 
0%), and injecting liquid opiates showed a strong and 
significant association with HCV (OR = 18.0; 95% CI = 
5.5–59.2) even after controlling for years since first in-
jecting in a preliminary bivariate logistic regression 
model.  Hungary versus Lithuania Drug Profile    Eur Addict Res 2010;16:220–228  223
Table 1.   Individual background, population mixing susceptibility, drug use patterns and syringe use and shar-
ing among Lithuanian and Hungarian IDUs
Characteristics Hungary Lithuania p value
Total 215 (100) 300 (100)
Tested positive for HCV1 69 (37.1) 260 (87.5) <0.01
Tested positive for HIV1 0 (0) 29 (9.8) <0.01
Individual background
Gender
Male 166 (77.2) 229 (76.3)
Female 49 (22.8) 71 (23.7) 0.82
Age, years 27.986.5 29.887.6 <0.01
Population mixing susceptibility
Ethnicity2
Roma 44 (20.5) 6 (2.0) <0.01
Russian N/A 150 (50.0)
Polish N/A 50 (16.7)
Number of languages participant speaks
Only one 67 (31.2) 3 (1.0)
Two 90 (41.9) 89 (29.7)
Three 45 (20.9) 172 (57.3)
Four or more 13 (6.0) 36 (12.0) <0.01
Travelled outside the capital in the past 12 months 138 (64.2) 137 (45.7) <0.01
Travelled outside the country in the past 12 months 44 (20.5) 25 (8.3) <0.01
Drug use patterns
Age at first use of legal drugs (alcohol or tobacco), years 12.483.0 14.082.3 <0.01
Age at first use of any illegal drug, years 15.085.3 15.884.4 0.09
Age at first drug injecting, years 20.586.0 19.284.4 <0.01
Years as non-injecting drug user 5.585.3 3.483.8 <0.01
Number of drugs ever tried 12.184.4 11.083.0 <0.01
Number of drugs ever injected 4.482.9 5.582.0 <0.01
Number of drugs injected in the past 30 days 1.580.9 2.981.2 <0.01
Number of drugs injected daily in the past 30 days 0.480.5 1.280.8 <0.01
Number of drugs non-injected in the past 30 days 3.781.7 2.982.0 <0.01
Number of drugs non-injected daily in the past 30 days 1.680.9 1.180.4 <0.01
Daily drug injecting 91 (42.3) 273 (91.0) <0.01
Drug injected most often in past 30 days
Heroin 147 (68.4) 198 (66.0)
Amphetamine purchased in powder form 61 (28.4) 12 (4.0)
Drugs purchased in liquid form 0 (0.0) 90 (30.0)
Other drugs 7 (3.3) 0 (0) <0.01
Injecting equipment use and sharing – past 30 days
Any use of 2-piece syringes
(vs. using only 1-piece syringes) 14 (5.2) 253 (94.8) <0.01
Any syringe/needle sharing (receptive or distributive) 71 (33.0) 294 (98.0) <0.01
Any sharing of other injecting equipment
(cookers, filters, syringe-mediated drug sharing) 133 (61.9) 285 (95.0) <0.01
F  igures in parentheses are percentages. N/A = Not assessed.
1 297 participants were tested in Lithuania and 186 participants were tested in Hungary.
2 More than 1 ethnic group could be checked. Gyarmathy   /Neaigus   /Li   /Ujhelyi   /
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  Discussion 
  This study compared individual backgrounds and 
patterns of population mixing susceptibility, drug use, 
syringe use and sharing, structural background markers, 
as well as attitude and knowledge among IDUs in Buda-
pest, Hungary, and Vilnius, Lithuania, in order to gain 
insight into what may lie behind the differences in HIV 
and HCV prevalence in these populations. Overall, com-
pared with IDUs in Hungary, IDUs in Lithuania often 
injected drugs purchased in liquid form, used and shared 
2-piece syringes disproportionately more often, were less 
likely to acquire their syringes from legal sources, and 
had more experience with injected and less experience 
with non-injected drugs.
  Liquid drugs, the sharing of syringes and other inject-
ing equipment, and syringe type go hand in hand, and 
together, may contribute to a risk environment that could 
explain the differences in HIV and HCV prevalence be-
tween Hungary and Lithuania. ‘Shirka’ (also known as 
hanka or kompot/kompót) is a home-made liquid opiate, 
which is cheaper than heroin, and is sold in large, pre-
loaded syringes  [16]  mostly in Gypsy camps in Lithuania. 
Not only are the preloaded syringes potentially non-ster-
Table 2.   Structural background markers, attitude and knowledge, and sexual risk characteristics of Lithuanian 
and Hungarian IDUs
Characteristics Hungary Lithuania p value
Total 215 (100) 300 (100)
Structural background markers
Ever in treatment 81 (37.7) 129 (43.0) 0.23
Currently in treatment 45 (20.9) 16 (5.3) <0.01
All syringes used were sterile 163 (75.8) 96 (32.0) <0.01
All syringes from the needle exchange
(primary or secondary exchange) 88 (40.9) 42 (14.0) <0.01
All syringes from the pharmacy 71 (33.0) 1 (0.3) <0.01
All syringes from either the needle exchange or the pharmacy 194 (90.2) 114 (38.0) <0.01
Any syringes from the dealer 2 (0.9) 108 (36.0) <0.01
Drugs most often injected with 1-piece syringe
(any 1-piece syringe use, n = 169) N/A
Heroin 151 (89.4)
Drugs purchased in liquid form 3 (1.8)
Amphetamine purchased in powder form 15 (8.9)
Drugs most often injected with 2-piece syringe
(any 2-piece syringe use, n = 253) N/A
Heroin 90 (35.5)
Drugs purchased in liquid form 129 (51.0)
Amphetamine purchased in powder form 30 (11.9)
Other 4 (1.6)
Attitude and knowledge
Agreement with both HIV and HCV infection
have to be disclosed to all injecting partners 212 (98.6) 250 (83.3) <0.01
HIV and HCV knowledge score 4.1 (1.1) 4.8 (0.5) <0.01
Sexual risk
Number of sexual partners in the past 30 days
None 90 (41.9) 77 (25.7)
One 89 (41.4) 109 (36.3)
Two or more 36 (16.7) 114 (38.0) <0.01
Number of sexual acts in the past 30 days 8.7814.9 7.5812.7 0.36
Always used condoms for sex 23 (10.7) 21 (7.0) 0.14
Figures in parentheses are percentages. N/A = Not assessed.  Hungary versus Lithuania Drug Profile    Eur Addict Res 2010;16:220–228  225
ile (maybe even contaminated with blood)   [17]  , but they 
also prevent IDUs from using their own, sterile syringes 
from the pharmacy or the needle exchange. Furthermore, 
while cleaning syringes may considerably reduce the 
probability of infection   [4]  , preloaded syringes may not 
be cleaned before sharing, because cleaning would flush 
out or dilute some or much of the drug in the syringe. 
There is a link between liquid drugs and the sharing of 
syringes and other injecting equipment   [12]  : the content 
of the large, preloaded syringes is usually shared with 
other injectors, which requires either syringe sharing or 
the sharing of other injecting equipment (sharing of 
cookers or syringe-mediated drug sharing); the preva-
lence of both was high among IDUs in Lithuania. In ad-
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  Fig. 1.   Non-injected drugs used daily by Lithuanian and Hungar-
ian IDUs. Alc = Alcohol; Glu = glue or inhalants; Her = heroin; 
Klo = klonopin or rivotril (i.e. clonazepam); Mar = marijuana; 
Mot = methadone from sources other than treatment; Mtx = 
methadone from treatment; Pop = poppy tea; Tob = tobacco;
Trn = tranquilizers; Xtc = ecstasy.   *  p   !   0.05, statistically signifi-
cant difference between proportions. 
  Fig. 2.   Drugs injected daily by Lithuanian and Hungarian IDUs. 
Amp = Amphetamines (purchased in powder form); Coc = co-
caine; Her = heroin; Ket = ketamine; Klo = klonopin or rivotril 
(i.e. clonazepam); Lia = amphetamines purchased in liquid form; 
Lio = opiates purchased in liquid form; Mot = methadone from 
sources other than treatment; Mtx = methadone from treatment; 
Trn = tranquilizers.   *  p   !   0.05, statistically significant difference 
between proportions. 
Table 3.   Variables that were associated with recruitment location in multivariate logistic regression model
Maximum likelihood
estimate
p value (2)
Any syringe/needle sharing (receptive or distributive) 6.5693 <0.0001
Any use of 2-piece syringes (vs. using only 1-piece syringes) 5.9863 <0.0001
Primary drug of injecting, amphetamine –3.5097 0.0014
All syringes from either the needle exchange or the pharmacy –3.3663 0.0002
Participant speaks 3 or more languages 2.4135 0.0044
Number of drugs non-injected daily in the past 30 days –1.9324 0.0056
Daily drug injecting 1.8573 0.0279
HIV and HCV knowledge score 1.3817 0.0087
Number of drugs injected daily in the past 30 days 1.1464 0.0702
Number of drugs ever tried –0.7634 0.0003
Number of drugs ever injected 0.6166 0.0369
Age at first use of any legal drug (alcohol or tobacco) 0.3923 0.0112 Gyarmathy   /Neaigus   /Li   /Ujhelyi   /
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dition, our results show another link with liquid drugs, 
namely with syringe type: almost all drugs that were 
most often injected with 1-piece syringes in Lithuania 
were drugs sold in powder form, while the majority of 
drugs that were most often injected with 2-piece syringes 
were drugs sold in liquid form. (Participants explained 
that drugs purchased in liquid from have many floating 
particles that would clog the thin needles of 1-piece sy-
ringes, so 2-piece syringes, which have wider needles, are 
more suitable for injecting liquid drugs.) Two-piece sy-
ringes have more dead space between the plunger and the 
needle than 1-piece syringes and retain a larger amount 
of blood even after cleaning   [18]  . There is increasing evi-
dence showing that the prevalence of both HIV and HCV 
infections is higher among IDUs who inject with 2-piece 
syringes compared with those who inject with 1-piece sy-
ringes only   [4, 13, 14] .
    However, based on prior research studies that defied 
the association between HIV and liquid drugs   [19] ,  it 
would be highly unfounded to suggest that liquid drugs 
by themselves are the reason for the higher prevalence of 
HCV and, especially, HIV in Lithuania. Abdala et al.  [19]  
found that the potential for transmission from injection 
of liquid forms of heroin is dramatically reduced when 
IDUs inject with liquid heroin made from either poppies 
or opium gum (as opposed to heroin manufactured and 
sold as a solid product) because the cycles of heating, 
acidification and acetylation as well as some component 
of the poppies inactivate HIV. Thus, in the light of previ-
ous findings, our results suggest that it may not be liquid 
drugs per se that contribute to a higher prevalence of 
HCV and/or HIV. Instead, the role of liquid drugs may be 
to create a risk environment that promotes high-risk in-
jecting practices, such as the wide-spread use and sharing 
of potentially contaminated 2-piece syringes acquired of-
ten from non-legal sources, syringe-mediated drug shar-
ing and syringe-mediated drug sharing with 2-piece sy-
ringes – all of which were extremely high among the Lith-
uanian IDUs. Based on this and our post-hoc analysis, 
the role of drugs sold in liquid form should be further in-
vestigated in terms of their contribution to a risky inject-
ing environment and high-risk injection practices. Such 
insight may provide an explanation to the paradox that 
while the process of liquid opiate production inactivates 
HIV, there are dramatically high levels of HIV among 
IDUs in, for example, the Ukraine who inject liquid opi-
ates   [20, 21] .
    Drug injecting culture may also contribute to the dif-
ferences in injecting and infections. IDUs in Hungary 
had less experience with injected and more experience 
with non-injected drugs. The reason for this may be that 
in Hungary, there is a centuries-old tradition of wine pro-
ducing and moderate drinking   [22]   (as witnessed by the 
significantly lower age of IDUs in Hungary at first legal 
drug use, particularly of alcohol use, in this study). In 
Europe, southern countries with wine-producing tradi-
tions have less binge drinking and drunkenness than 
northern countries with no wine-producing traditions, 
probably because the idea of moderate consumption is 
integrated into everyday life   [23]  . The Hungarian wine 
drinking traditions may be reflected in Hungarian drug 
users’ drug taking habits in a way that they prefer more 
‘moderate’ drug taking   [24]  . However, this is only a hy-
pothesis that cannot be confirmed in this study.
    The finding that Lithuanian IDUs were more likely to 
speak 3 or more languages is certainly linked to the high-
er number of ethnic groups in Lithuania. While we did 
not assess fluency in these languages in the question-
naire, our interviewers in Hungary reported that most 
participants said they spoke only a little bit of, while our 
interviewers in Lithuania reported that most participants 
said they were fluent in the reported languages. Lack of 
language knowledge may prevent Hungarian IDUs from 
mixing with other IDUs visiting Hungary from higher-
prevalence countries, and thus, becoming infected, while 
language fluency, especially of Russian, in multi-ethnic 
Lithuania may contribute to more population mixing and 
opportunity for infection.
    Limitations of this analysis include that comparing 
country differences is no evidence for causality. However, 
the goal of this analysis was not to imply causality but to 
provide new hypotheses and suggestions for further re-
search. Another limitation is that while IDUs in Lithua-
nia were initially recruited from the needle exchange pro-
gramme, IDUs in Hungary were initially recruited from 
the street. However, most participants were recruited 
through other participants at both locations, which prob-
ably reduced the potential initial recruitment bias, and 
when we included frequency of syringe exchange atten-
dance in the final multivariate model as a control vari-
able, there was no change in the variable selection. An-
other limitation is that data collection in Vilnius started 
2 years after data collection ended in Hungary. While the 
drug use population and habits may have changed during 
this time in Hungary, we believe this to be very unlikely 
since there was no change in the availability or quality of, 
or access to, prevention programmes targeting IDUs in 
Hungary, and the drug profile of these participants was 
very similar to those in our earlier studies  [25] , suggesting 
negligible changes in secular trends. A further limitation   Hungary versus Lithuania Drug Profile    Eur Addict Res 2010;16:220–228  227
is that the injection of drugs purchased in liquid form
was not assessed in Hungary . This drug category was
not included because preliminary ethnographic findings 
showed that while some reported using liquid opioids in 
the past  [26] , these drugs were no longer available in Hun-
gary. However, the questionnaire for this study included 
a question asking whether they used any drugs other than 
the ones mentioned and what these drugs were, and not 
only did nobody in Hungary mention ‘kompót’, but par-
ticipants also commented on how exhaustive the drug list 
was. Another limitation is that the 2 populations were not 
random samples of the IDU populations in these 2 coun-
tries, which indicates that the representativeness of and 
generalization from these findings may be limited. A 
range of differences, both measured and unmeasured, 
may also contribute to the differences in HIV and HCV 
among the 2 IDU populations. While the differences in 
HIV and HCV prevalence may be a result of differences 
in the implementation of harm reduction interventions (a 
quantitative aspect of HIV/HCV infection risk), our find-
ings provide suggestions for further exploring the role of 
liquid opiates and 2-piece syringes (a qualitative aspect of 
HIV/HCV infection risk).
    This study highligh ts that the a vailab ili ty o f large-
scale HIV prevention programmes (such as legal access 
to sterile syringes and drug treatment) may not be enough 
to keep the prevalence of drug-related blood-borne infec-
tions low when the risk environment   [16]   is such that it 
considerably contributes to high-risk injecting. One such 
risk environment in Lithuania seems to be the wide-
spread injecting of drugs sold in liquid form, leading to 
high-risk injecting, such as the wide-spread use and shar-
ing of potentially contaminated 2-piece syringes acquired 
often from non-legal sources, syringe-mediated drug 
sharing and syringe-mediated drug sharing with 2-piece 
syringes. Although this hypothesis needs to be further 
tested, it suggests that a possible intervention to reduce 
HIV and HCV among IDUs in Lithuania would be to re-
duce the prevalence among them of injecting drugs sold 
in liquid form, especially liquid opiates. This could be ac-
complished by a combination of supply and demand re-
duction. Supply reduction would involve increasing po-
lice activities, to reduce the sale of drugs sold in liquid 
form. However, this alone may lead to the illegal sales of 
other drugs and a shift in the drug market   [27]   and may 
add to the pressure on Roma, Russian and Polish minor-
ities. To counterbalance the unwanted effect of such sup-
ply reduction, there needs to be a parallel reduction in the 
demand for those new illegal drugs by increasing the 
availability of and access to legal drugs that meet the 
needs of active IDUs who are not ready or willing to stop 
injecting at that time  [28] . Methadone maintenance treat-
ment has been available in Lithuania since 1996 and in 
Hungary since 1995, high-dosage buprenorphine treat-
ment in Lithuania since 2002, and buprenorphine/nalox-
one combination in Hungary since 2007   [11] .  However, 
these treatment forms may not suit the needs of active 
drug injectors who do not wish to stop or reduce drug 
injecting. A treatment form that is more suitable for such 
a population is heroin-assisted treatment, which has been 
shown to significantly decrease the injecting of street 
drugs, engaging in syringe sharing, alcohol consumption 
and the prevalence of HCV and maybe HIV infections 
  [29–37]  . Heroin-assisted treatment is now the standard 
treatment in 6 European Union member states (Belgium 
since 2007, Denmark since 2008, Germany and Spain 
since 2003, The Netherlands since 1998, and the United 
Kingdom since the 1920s)   [11]  , but not yet in either Hun-
gary or Lithuania. Lithuanian authorities may want to 
consider adopting heroin-assisted treatment as a way to 
decrease the demand for and the prevalence of injecting 
opiates sold in liquid form, and thus, the use and sharing 
of (potentially contaminated) 2-piece syringes, and, on 
the longer run, decrease the prevalence of drug-related 
blood-borne infections among IDUs, including a further 
spread of HIV. In addition, increasing the availability of 
and access to psychosocial treatment, peer self-help orga-
nizations and brief interventions in general medical set-
tings may be useful tools of demand reduction in Lithu-
ania as well   [38] .
    This study provides initial data on an important but 
challenging topic. Research over the previous 25 years 
has made it clear that simple rates of syringe sharing and 
unprotected intercourse do not adequately explain cross-
national (and sometimes within-country) variations in 
HIV prevalence among IDUs. Accordingly, cross-nation-
al studies like this are essential to help identify and clar-
ify factors beyond simple risk behaviours that may help 
understand differences in HIV prevalence.
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